Business

OXB to present at the Leerink Partners Global Healthcare Conference

OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11 March 2025 at 2:20 PM EDT / 6:20 PM GMT. A live webcast of the fireside chat will be available on the ‘Investor Relations’ section of

articleOxford Biomedica PlcFebruary 26, 20252/company/oxford-biomedica-plc/news/oxb-to-present-at-the-leerink-partners-global-healthcare-conference
OXB to present at the Leerink Partners Global Healthcare Conference

About this update from Oxford Biomedica Plc

[{"type":"image","alt":"OXB","displaySize":"","headline":null,"caption":"OXB","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fa8vdAQ1u36jC9pq9QpcgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2","width":300,"height":159}},"lazy":false},{"type":"text","content":"OXB to present at the Leerink Partners Global Healthcare Conference ","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11 March 2025 at 2:20 PM EDT / 6:20 PM GMT.","length":344,"tagName":"p"},{"type":"text","content":"A live webcast of the fireside chat will be available on the ‘Investor Relations’ section of OXB’s website under ‘Results, Reports, Presentations & Webcasts’ at www.oxb.com. A replay will be accessible following the event.","length":226,"tagName":"p"},{"type":"text","content":"-Ends-","length":6,"tagName":"p"},{"type":"text","content":"Enquiries:","length":10,"tagName":"p"},{"type":"text","content":"OXB:","length":4,"tagName":"p","attribs":{}},{"type":"text","content":"Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: [email protected]","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"ICR Healthcare:T: +44 (0)20 3709 5700 / E: [email protected]","length":70,"tagName":"p","attribs":{}},{"type":"text","content":"Mary-Jane Elliott / Angela Gray / Davide Salvi","length":46,"tagName":"p"},{"type":"text","content":"About OXB","length":9,"tagName":"p"},{"type":"text","content":"OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.","length":239,"tagName":"p","attribs":{}},{"type":"text","content":"One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral ...

More updates from Oxford Biomedica Plc

OXBgene therapyLeerink Partnersfireside chatglobal qualityOxford, UKviral vectors